Marzia Leotta has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CO-75 | ASSAY DISCREPANCY IN HEMOPHILIA A CARRIERS: CLINICAL AND GENETIC INSIGHTS

    by Marzia Leotta

    Background. Hemophilia A (HA) is an X-linked coagulopathy caused by F8 gene mutations. While research often focuses on males, female carriers frequently experience hemorrhagic diathesis due to skewed X-chromosome inactivation (lyonization). A critical diagnostic challenge is "assay discrepancy," where Factor VIII activity (FVIII:C) yields conflicting results between the One-Stage Clotting Assay (OSA) and the Chromogenic Substrate Assay (CSA). This study evaluates the incidence of these variations and their impact on clinical phenotyping in female carriers.Methods. A cross-sectional analysis was conducted on 16 confirmed F8 mutation carriers. FVIII:C was quantified via OSA: Based on the activated partial thromboplastin time (aPTT). CSA: Assessing the kinetics of Factor Xa (FXa) generation. Inter-assay discrepancy was defined as a CSA/OSA ratio < 0.6 or > 1.6. Genotype-phenotype correlation was performed to identify mutations associated with divergent biochemical profiles.Results. Data indicates that 50% of carriers exhibit a significant discrepancy, which was exclusively unidirectional (OSA > CSA). This systematic overestimation by the OSA may mask underlying functional deficiencies, leading to the misclassification of carriers as "hemostatically normal." In patients with "discrepancy-prone" mutations, traditional clotting assays failed to reflect clinical bleeding symptoms (ISTH-BAT scores), whereas the CSA superiorly represented the in vivo stability of the tenase complex. Specific molecular drivers identified include: Intron 10 Inversion (INV 10) and missense variants (Exons 4 and 7) consistently fall into the critical discrepancy zone (< 0.6). With ratios as low as 0.4, these mutations cause the OSA to significantly inflate FVIII levels, as seen in Patient 8 (60% OSA vs. 24% CSA). For these specific genotypes, the 0.6 threshold confirms that the OSA is unreliable and risks masking a patient's true bleeding vulnerability. Conversely, the two methods begin to converge (> 0.6) primarily in INV 22 cases (specifically Patients 11 and 12), where ratios reach 0.8–0.9. In this range, the discrepancy narrows enough that the OSA and CSA can be considered clinically consistent. Ultimately, your data identifies the 0.6 ratio as the decisive "red line": any mutation pushing the ratio below this mark, like INV 10, mandates the use of the chromogenic assay to ensure diagnostic safety.Conclusions. Dependence on the One-Stage Assay (OSA) alone offers an incomplete assessment of the hemostatic profile in carriers. The observed OSA/CSA divergence represents a distinct biological phenomenon rooted in altered protein kinetics. To enhance clinical safety, specifically regarding perioperative management, the implementation of a dual-assay diagnostic strategy is essential. Such an approach ensures that therapeutic interventions are informed by a precise measurement of true physiological coagulant capacity.

  • Open Access

    CO-72 | HEREDITARY FACTOR X DEFICIENCY UNMASKED BY NECROTIZING HEMORRHAGIC PANCREATITIS: A CASE REPORT

    by Marzia Leotta

    Background. Factor X (FX) deficiency is one of the rarest coagulation disorders, typically manifesting as an autosomal recessive trait. While clinicians often suspect an acquired deficit in the presence of severe systemic inflammation or major necrotic events, such as necrotizing hemorrhagic pancreatitis (NHP), the possibility of an underlying genetic condition must be considered when the coagulopathy appears disproportionate to the clinical state. NHP creates a high-risk environment for both massive hemorrhage and thrombosis. This case report discusses the diagnostic journey of a patient whose critical illness led to the discovery of a familial coagulation defect, fundamentally changing the therapeutic approach.Case Report. A 72-year-old male (born 11/11/1953) was transferred from the Gastroenterology department following severe NHP. His condition was complicated by a resuscitative cardiopulmonary (RCP) event, resulting in a vast peripancreatic hematoma and splenic vein thrombosis. Laboratory tests showed a PT ratio of 1.24 and an aPTT ratio of 1.53. Specific assays revealed a Factor X activity of 26%. Initially, an acquired deficiency was strongly suspected due to potential factor consumption within the hematoma or proteolytic degradation by pancreatic enzymes. However, to clarify the etiology, a familial screening was conducted. Surprisingly, both of the patient's daughters were found to have a similar Factor X deficiency, shifting the diagnosis from acquired to hereditary Factor X deficiency. To identify the causative mutation, genetic analysis via sequencing of the F10 gene is currently ongoing. Despite the hemorrhagic risk posed by the vast hematoma and the genetic deficit, the patient required anticoagulation for the splenic vein thrombosis. He was started on Fondaparinux. Currently, the patient is stabilized and awaiting a follow-up abdominal CT scan to monitor the hematoma’s evolution and the efficacy of the anticoagulation in the context of this newly identified genetic risk factor.Conclusions. This case demonstrates that while necrotizing hemorrhagic pancreatitis can exacerbate coagulopathy, an unexpectedly low Factor X level (26%) should prompt an investigation into the patient’s genetic background. The discovery of the same deficit in both daughters confirms a hereditary rather than a purely acquired etiology. Genetic testing, which is currently underway to identify the specific F10 gene mutation, and family screening are essential in these rare scenarios to provide accurate diagnosis, genetic counseling, and tailored hematological management for both the patient and their relatives. Frequent radiological monitoring remains the gold standard for navigating this complex clinical equilibrium.

  • Open Access

    CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES

    by Marzia Leotta

    Background. Acquired Hemophilia A (AHFA) is a rare bleeding disorder caused by the development of neutralizing autoantibodies against endogenous coagulation factor VIII (FVIII). The clinical presentation is often characterized by sudden, severe subcutaneous and mucosal hemorrhages. Management is inherently complex: it requires the immediate restoration of hemostasis and the simultaneous eradication of the inhibitor via immunosuppressive therapy (IST). Given that AHA predominantly affects the elderly population, treatment must be carefully tailored to account for multiple comorbidities and a high baseline thrombotic risk. This study provides a deep dive into the efficacy of rpFVIII as a first-line agent and analyzes the long-term clinical outcomes and challenges in a real-world setting.Methods. We conducted a retrospective observational study of 11 consecutive patients (7 males, 4 females) with AHA. The median age at diagnosis was 78 years (24–88). At presentation, the median residual FVIII level was 2.0%, while the median inhibitor titer was 13.5 Bethesda Units (BU), though the cohort included a significant outlier at 269 BU. The clinical complexity was high: 7 patients (64%) presented a significant baseline thrombotic risk, 5 (45%) had a history of or active malignancy, and 3 were receiving oral anticoagulant therapy (2 on Coumadin, 1 on DOAC) for underlying atrial fibrillation or TEV. Additionally, two cases were identified following recent COVID-19 infection, one of which was a fourth reinfection, suggesting a potential immunological trigger.Results. Active hemostatic treatment was required for 8 patients (73%). rpFVIII was utilized as the primary first-line hemostatic agent at an initial dosage of 100 mg/kg. The median number of administrations required to achieve stable hemostasis was 5.5 (mean: 5.25; range: 1–8). Two patients required a switch to second-line therapy with rFVIIa due to the development of anti-porcine FVIII antibodies (ADA), with titers reaching 30 and 45 BU. One patient was successfully transitioned to Emicizumab prophylaxis (starting 24 days post-diagnosis). The median time to inhibitor eradication was 21 days (mean: 25.9 days; range: 6–56). Relapse occurred in only one patient (the outlier patient) following self-discontinuation of steroid therapy. Post-eradication, two deaths occurred due to unrelated causes (urological sepsis and stroke), and two patients were lost to follow-up.Conclusions. rpFVIII proved to be an effective first-line hemostatic agent, particularly in elderly patients with complex comorbidities. However, the development of anti-ADA antibodies remains a critical factor that may necessitate a therapeutic switch. Our data confirm that a standardized IST approach achieves inhibitor eradication in a median of three weeks, though high-titer patients require strict monitoring and adherence to prevent relapses.

  • Open Access

    BEST-07 | ULTRASOUND EVALUATION AND JOINT SCORING IN MILD HEMOPHILIA A: A SINGLE-CENTER CASE SERIES FOR THE IDENTIFICATION OF SUBCLINICAL ARTHROPATHY

    by Marzia Leotta

    Background. Mild Hemophilia A (FVIII 5–40%) is often underestimated, yet patients remain at risk for chronic arthropathy due to subclinical bleeds and trauma. Since the HJHS (physical exam) often misses early damage, this study uses Point-of-Care Ultrasound (POCUS) to detect early synovial and osteochondral changes. The goal is to correlate clinical data, including Body Mass Index (BMI), with ultrasound findings to better assess true joint health.Materials and Methods. A cross-sectional analysis was conducted on a series of patients with mild hemophilia followed at our institution in the last year. For each patient, the primary target joints (elbows, knees, and ankles) were evaluated. The HJHS was administered to quantify functional joint impairment. BMI was recorded for all participants to evaluate the impact of body weight on joint health. POCUS scans were performed using the HEAD-US (Hemophilia Early Arthropathy Detection with Ultrasound) protocol. Correlation was assessed between baseline clotting factor levels, BMI, HJHS, and the total HEAD-US score.Results. A total of 36 mild patients are currently followed at our center; 23 male patients underwent HJHS and HEAD-US within the last 12 months. The median age was 40.6 years (range 12–65), and the mean BMI was 25.73 kg/m². The median baseline factor level was 10% (range 5-24%). The median ABR was remarkably low (0.4). The median HJHS score was 7.23 (range 0–16). HEAD-US scoring revealed structural abnormalities in 56.5% of the evaluated patients (13 pz). Notably, within a subgroup of 13 patients particularly susceptible to joint changes, 4 (33.3%) presented both osteostructural alterations and a BMI >25 kg/m². Mild synovial hypertrophy was detected in 23% of cases, and significant cartilage thinning was observed in 69% of subjects.Discussion. Our findings demonstrate that mild hemophilia does not preclude chronic arthropathy, which is more accurately detected by HEAD-US than by HJHS. The significant correlation between age and HEAD-US scores, alongside the impact of BMI >25 on structural damage, suggests that mechanical stress and cumulative trauma, rather than factor deficiency alone, are the primary drivers of joint degradation in this cohort. Consequently, the presence of osteostructural damage in overweight patients emphasizes the critical role of weight management. Integrating routine ultrasound into clinical follow-up allows for a more personalized therapeutic approach.Conclusions. Systematic HEAD-US evaluation facilitates preclinical arthropathy diagnosis in mild hemophilia. Monitoring should integrate periodic imaging and metabolic assessments, such as BMI, to ensure a proactive, personalized strategy that preserves long-term quality of life.

  • Open Access

    The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey

    by Silvia Linari, Renato Marino, Marzia Leotta, Antonio Coppola, Patrizia Di Gregorio, Augusto Bramante Federici, Flora Peyvandi, Cristina Santoro, Ezio Zanon, Rita Carlotta Santoro

    Background: Rare bleeding disorders (RBDs) are a group of inherited conditions caused by deficiencies in specific coagulation factors, excluding hemophilia A/B and von Willebrand disease. Individually rare, they pose a significant challenge for diagnosis and management due to diverse clinical presentations and low awareness. This study aimed to provide an overview of RBDs.Methods: An online survey was sent to Italian hemophilia treatment centers.Results: Nineteen centers responded. The diagnostic approach was tiring, but key definitions showed significant variability. This included defect severity, target hemostatic levels for surgery, eligibility thresholds for rare disease exemptions. The use of prophylaxis varied, although favored in severe FII, FVII, FX, and FXIII defects. Treatment primarily involved factor-specific concentrates and tranexamic acid. While inhibitor development was considered uncommon, it was a recognized risk. Bleeding management during dental procedures, pregnancy, and delivery also showed variability. Additionally, normal factor levels in neonates differed across centers.Conclusions: This study highlights a good consensus for managing certain RBDs (FII, FVII, FX, FXIII) in Italy. However, significant heterogeneity persists, emphasizing the need for greater standardization and further research in several key areas.

  • Open Access

    Hemostasis Laboratory Diagnostics in Newborns

    by Chiara Gorio, Angelo Claudio Molinari, Tiziano Martini, Antonietta Ferretti, Giulia Albrici, Giulia Carracchia, Antonella Ierardi, Marzia Leotta, Nicola Portesi, Monica Sacco, et al.

    The hemostatic system in the newborn is a complex entity, characterized by dynamism in its development; therefore, the correct measurement of its potential is challenging. In this narrative review, we analyzed the current knowledge of the “developmental hemostasis” of the newborn; we also studied the performance of routine coagulation tests in its evaluation, with considerations about the establishment of neonatal age-specific normal ranges and about the role of preanalytical variables, in particular, hematocrit (which could represent an important cause of error); we also focused on the increasing importance of viscoelastic coagulation tests, which are becoming increasingly widespread (especially in some settings such as intensive care unit) and are able to quickly provide information about the hemostatic function of the newborn, even if they lack adequate standardization in the neonatal period.


  • Open Access

    Prolongated Activated Partial Thromboplastin Time (aPTT) in Pediatric Patients before Surgery—Crying Wolf: Lupus (Anticoagulant) Does Not Always Threaten Children

    by Tiziano Martini, Rita Carlotta Santoro, Laura Banov, Antonella Ierardi, Marzia Leotta, Alessandra Strangio, Johanna Svahn, Angelo Claudio Molinari

    A prolonged preoperatory aPTT in children is often the cause of a delay of scheduled surgeries and the repetition of multiple blood tests, with the consequent wasting of resources and significant discomfort for children and parents. The aim of this review is to analyze the situations in which an isolated prolongation of aPTT is found during preoperative evaluation in children, especially when it is due to the presence of antiphospholipid antibodies, providing the readers with the keys to interpret this situation and the possibility to correctly evaluate the hemorrhagic risk of a patient.


  • Open Access

    Lupus Anticoagulant Detection under the Magnifying Glass

    by Angelo Claudio Molinari, Tiziano Martini, Laura Banov, Antonella Ierardi, Marzia Leotta, Alessandra Strangio, Rita Carlotta Santoro

    Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis and/or pregnancy morbidity), combined with persistently circulating antiphospholipid antibodies (aPL). Lupus anticoagulant (LA) is one of the three laboratory parameters (the others being antibodies to either cardiolipin or β2-glycoprotein I) that defines this rare but potentially devastating condition. For the search for aCL and aβ2-GP-I, traditionally measured with immunological solid-phase assays (ELISA), several different assays and detection techniques are currently available, thus making these tests relatively reliable and widespread. On the other hand, LA detection is based on functional coagulation procedures that are characterized by poor standardization, difficulties in interpreting the results, and interference by several drugs commonly used in the clinical settings in which LA search is appropriate. This article aims to review the current state of the art and the challenges that clinicians and laboratories incur in the detection of LA.


  • Open Access

    Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!

    by Rita Carlotta Santoro, Angelo Claudio Molinari, Marzia Leotta, Tiziano Martini

    Activated partial thromboplastin time (aPTT) is a fundamental screening test for coagulation disturbances. An increased aPTT ratio is quite common in clinical practice. How the detection of prolonged activated aPTT with a normal prothrombin time is interpreted is therefore very important. In daily practice, the detection of this abnormality often leads to delayed surgery and emotional stress for patients and their families and may be associated with increased costs due to re-testing and coagulation factor assessment. An isolated, prolonged aPTT is seen in (a) patients with congenital or acquired deficiencies of specific coagulation factors, (b) patients receiving treatment with anticoagulants, mainly heparin, and (c) individuals/patients with circulating anticoagulants. We summarize here what may cause an isolated prolonged aPTT and evaluate the preanalytical interferences. The identification of the cause of an isolated prolonged aPTT is of the utmost importance in ensuring the correct diagnostic workup and therapeutic choices.


  • A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells

    by Marzia Leotta, Lavinia Biamonte, Lavinia Raimondi, Domenica Ronchetti, Maria Teresa Di Martino, Cirino Botta, Emanuela Leone, Maria Rita Pitari, Antonino Neri, Antonio Giordano, et al.

    The analysis of deregulated microRNAs (miRNAs) is emerging as a novel approach to disclose the regulation of tumor suppressor or tumor promoting pathways in tumor cells. Targeting aberrantly expressed miRNAs is therefore a promising strategy for cancer treatment. By miRNA profiling of primary plasma cells from multiple myeloma (MM) patients, we previously reported increased miR‐125a‐5p levels associated to specific molecular subgroups. On these premises, we aimed at investigating the biological effects triggered by miR‐125a‐5p modulation in MM cells. Expression of p53 pathway‐related genes was down‐regulated in MM cells transfected with miR‐125a‐5p mimics. Luciferase reporter assays confirmed specific p53 targeting at 3′UTR level by miR‐125a‐5p mimics. Interestingly, bone marrow stromal cells (BMSCs) affected the miR‐125a‐5p/p53 axis, since adhesion of MM cells to BMSCs strongly up‐regulated miR‐125a‐5p levels, while reduced p53 expression. Moreover, ectopic miR‐125a‐5p reduced, while miR‐125‐5p inhibitors promoted, the expression of tumor suppressor miR‐192 and miR‐194, transcriptionally regulated by p53. Lentiviral‐mediated stable inhibition of miR‐125a‐5p expression in wild‐type p53 MM cells dampened cell growth, increased apoptosis and reduced cell migration. Importantly, inhibition of in vitro MM cell proliferation and migration was also achieved by synthetic miR‐125a‐5p inhibitors and was potentiated by the co‐expression of miR‐192 or miR‐194. Taken together, our data indicate that miR‐125a‐5p antagonism results in the activation of p53 pathway in MM cells, underlying the crucial role of this miRNA in the biopathology of MM and providing the molecular rationale for the combinatory use of miR‐125a inhibitors and miR‐192 or miR‐194 mimics for MM treatment. J. Cell. Physiol. 229: 2106–2116, 2014.